Efavirenz exposure, alone and in combination with known drugs of abuse, engenders addictive-like bio-behavioural changes in rats

Marisa Möller, Jaco Fourie & Brian H. Harvey

Efavirenz is abused in a cannabis-containing mixture known as Nyaope. The addictive-like effects of efavirenz (5, 10 and 20 mg/kg) was explored using conditioned place preference (CPP) in rats following sub-acute exposure vs. methamphetamine (MA; 1 mg/kg) and Δ9-tetrahydrocannabinol (THC; 0.75 mg/kg). The most addictive dose of efavirenz was then compared to THC alone and THC plus efavirenz following sub-chronic exposure using multiple behavioural measures, viz. CPP, sucrose preference test (SPT) and locomotor activity. Peripheral superoxide dismutase (SOD), regional brain lipid peroxidation and monoamines were also determined. Sub-acute efavirenz (5 mg/kg) had a significant rewarding effect in the CPP comparable to MA and THC. Sub-chronic efavirenz (5 mg/kg) and THC + efavirenz were equally rewarding using CPP, with increased cortico-striatal dopamine (DA), and increased lipid peroxidation and SOD. Sub-chronic THC did not produce CPP but significantly increased SOD and decreased hippocampal DA. Sub-chronic THC + efavirenz was hedonic in the SPT and superior to THC alone regarding cortico-striatal lipid peroxidation and sucrose preference. THC + efavirenz increased cortico-striatal DA and decreased serotonin (5-HT). Concluding, efavirenz has dose-dependent rewarding effects, increases oxidative stress and alters regional brain monoamines. Efavirenz is hedonic when combined with THC, highlighting its abuse potential when combined with THC.

More than 56% of people living with human immunodeficiency virus (HIV) receive antiretroviral therapy (ART), which consists primarily of two nucleoside reverse transcriptase inhibitors (NRTI’s) such as zidovudine and lamivudine, and one non-nucleoside reverse transcriptase inhibitor (NNRTI) of which efavirenz ((4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one) is the most popular1. Efavirenz is associated with a range of neuropsychiatric side effects (see2 for review), with manic episodes, euphoria and dissociative effects particularly noteworthy3,4. Efavirenz is a lipophilic compound5, which may underlie its penchant for mediating a diverse range of CNS manifestations2. Preclinical studies indicate that efavirenz acts as a weak partial agonist at the serotonin 5-HT2A receptor6, while also presenting with actions at dopamine (DA) and 5-HT transporters, thus in line with other drugs of abuse7,8.

Crushing and smoking of an efavirenz- cannabis mixture, commonly known as “Nyaope” or “Woonga”9, in certain countries like South Africa, has seen the recreational use and abuse of efavirenz escalate to alarming proportions9. With other HIV drugs, like dolutegravir10, also noted for presenting with a similar neuropsychiatric side-effect profile, there is an urgent need to identify possible mechanisms that might relate to the rewarding effects and addictive-like/abuse potential of these drugs and as such to devise possible treatments.

Addictive disorders share a number of common neurobiological substrates critical in reward and reinforcement, in particular the mesocorticolimbic DA pathway11, as well as 5-HT and noradrenalin (NA) related processes12. In fact, all major classes of drugs of abuse increase the levels of these monoamines in the frontal cortex, striatum and hippocampus, whereby they are purported to mediate euphoria, arousal, reward and relapse in humans13,14. However, drugs such as cocaine and methamphetamine (MA) are pro-oxidants, thereby implicating disordered redox pathways not only in the development of addiction15 but also mediating neuronal damage so often engendered by the abuse of these drugs16.
Exposure of rats to efavirenz (10 and 30 mg/kg) has been found to significantly decrease exploratory behaviour, although without evidence for addictive-like effects, while another study described anxiogenic and depressogenic effects following acute and sub-chronic doses of efavirenz (25 and 50 mg/kg, respectively). The authors also found that acute doses of efavirenz (25 mg and 50 mg/kg) increased striatal DA, 5-HT and NA, with sub-chronic exposure having the opposite effect. Thus, dose-related neurochemical and psychotropic effects are evident with efavirenz, at least in animals. However, its addictive-like properties with relation to dose and in comparison to known drugs of abuse, and its ability to bolster the actions of the latter drugs, requires further study.

The aim of this study was therefore to assess dose-dependent rewarding and addictive-like properties of efavirenz in a sub-acute study compared to MA and delta-9-tetrahydrocannabinol (THC), utilizing the conditioned place preference (CPP) test. Using the most effective dose, efavirenz was then studied in a sub-chronic exposure paradigm versus THC. The latter was chosen due to the often abused combination of efavirenz and cannabis. Alterations in addictive, hedonic and locomotor behaviour were assessed using the CPP test, sucrose preference test (SPT) and open field test (OFT) respectively, together with assay of frontal cortical, striatal and hippocampal monoamines. Additionally, changes in brain lipid peroxidation and peripheral redox status by assessing superoxide dismutase (SOD) activity. Lastly, combined sub-chronic efavirenz plus THC exposure was investigated to establish any possible augmenting actions with regard to the above responses.

**Material and Methods**

**Statement on ethics.** The study and article were conducted and presented according to the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines, as previously described. The animals were handled according to the code of ethics in research, training and testing of drugs in South Africa with appropriate ethical approval (NWU - 00267-16-5; North-West University animal research ethics committee (AnimCare); NHREC reg. number AREC-130913-015).

**Animals.** Male adult Sprague-Dawley (SD) rats, weighing 200 – 250g at the beginning of drug exposure (Vivarium, North West University), were randomized to 12 rats per experimental group with a total of 12 groups (n = 84 for the sub-acute study and n = 60 for the sub-chronic study). The rats were housed under identical conditions in the vivarium (SAVC reg. no. FR15/13458; SANAS GLP compliance no. G0019): cages (230(h) × 380(w) × 380(1 mm)) with corncob, temperature (21 ± 2°C), humidity (50 ± 10%), white light (350–400 lux), 12 h light/dark cycle and free access to food and water.

**Study design.** This study comprises a sub-acute and sub-chronic cohort. The former is a dose-finding behavioural study for later application to evaluate the possible enduring changes in the behavioural and neurobiological response of long-term exposure to efavirenz alone and in combination with THC. The sub-acute study consisted of 7 exposure groups receiving either MA (1 mg/kg), THC (0.75 mg/kg), efavirenz (at 5, 10 and 20 mg/kg), vehicle for MA (saline) and vehicle for THC and efavirenz (pharmaceutical grade olive oil), as illustrated in Fig. 1A. The sub-chronic study consisted of 5 groups receiving either efavirenz (at the most rewarding dosage as determined in the sub-acute study), THC (0.75 mg/kg), THC + efavirenz or vehicle (saline and olive oil respectively), as indicated in Fig. 1B. A saline control was also introduced in the sub-chronic study in order to rule out any potential antioxidant effects of olive oil as a vehicle for THC and efavirenz. All animals were randomly assigned to a specific drug exposure group, making use of a block randomization method. Drug exposure lasted for 6 days in the sub-acute study and 14 days in the sub-chronic study (with alternate day dosing) for the CPP paradigm. The sub-chronic study also included the following behavioural analyses: the OFT (day 13 of exposure) and SPT (day 4 and 14 of exposure). All animals were euthanized (via decapitation) 24 hrs after the last behavioural test (CPP post-conditioning test) in the sub-chronic study, whereupon regional brain tissue as well as trunk blood were collected for later assay.

**Drugs and drug exposure protocol.** All drugs and vehicles were injected intra-peritoneally (i.p) at 9:00 am. Vehicle, consisting of saline and pharmaceutical grade olive oil and adjusted to an average physiological pH, was administered on the days of vehicle exposure. Olive oil was used as a vehicle for both THC and efavirenz, which are lipophilic drugs. Efavirenz (5, 10 or 20 mg/kg/day), THC (0.75 mg/kg) and MA (methamphetamine hydrochloride (1 mg/kg)) administered on days of drug exposure. The MA and THC dosages were based on previous studies indicating CPP. In the sub-acute study animals were exposed to drug (MA, THC or efavirenz) on the mornings of days 1, 3 and 5 and vehicle on days 2, 4 and 6 of drug exposure. Two control groups of animals only received vehicle (saline or olive oil respectively) throughout the 6 days of exposure. These specific vehicles do not induce a place preference in the CPP test.

The sub-chronic exposure procedure also alternated between an illicit drug and efavirenz on one day followed by a vehicle exposure on the next day, lasting for 14 days. Thus, the sub-chronic groups received efavirenz, THC or THC + efavirenz on days 1, 3, 5, 7, 9, 11 and 13 and vehicle on days 2, 4, 6, 8, 10, 12, 14, following previous protocols. The two vehicle control groups received the respective vehicle exposure throughout the 14 days of exposure.

**Body weight.** The body weight of all animals was determined on post-natal day (PND) 21 and again on each day of drug exposure.

**Behavioural analysis.** Conditioned place preference test (CPP). The rewarding or aversive properties of a drug can be assessed in the CPP test (reviewed in). The CPP apparatus and paradigm used for this study was adapted from and validated in our laboratory. Briefly, conditioned testing was conducted in a three-compartment apparatus, constructed of plexiglass and separated by guillotine doors. The two large end compartments (24 × 35 cm) was separated by a smaller centre “choice” compartment (15.5 × 19.5 cm), and used...
on the habituation and test days. The two outer compartments were visually different and had different floor textures. The CPP paradigm consisted of 3 different stages: (1) a habituation stage (day 1), performed the day before drug exposure, where animals were allowed free access to all 3 compartments for 20 minutes and the compartment in which the least time is spent is then assigned as "the drug-paired compartment" with the most preferred compartment assigned as "the vehicle-paired compartment"; (2) a conditioning stage (days 1–6 for sub-acute or 9–14 for sub-chronic) where animals were injected with either the test drug and subjected to the drug-paired compartment, or vehicle and subjected to the vehicle-paired compartment for 20 minutes; (3) a post-conditioning stage (the day after the last exposure) where animals were allowed free access to all the compartments for 20 minutes, whereupon the time spent in each compartment was assessed. More time spent in the drug-paired compartment (preference) is evidence of a rewarding drug, while less time spent in the drug-paired compartment evidence of an aversive drug.

Behaviour was recorded under dim white light (40 Lux) with a digital video camera and blindly scored using EthoVision® XT software (Noldus Information Technology, Wageningen, Netherlands). The time spent in each compartment prior and post-conditioning was scored. The CPP data is presented as the difference in time spent in the drug-paired compartment utilising the following formula:

\[
\text{Time spent in drug-paired compartment during post-test (s)} - \text{Time spent in the drug-paired compartment during habituation (s)}
\]

Open field test (OFT). The psychomotor stimulant theory of drugs of abuse suggests that most drugs of abuse alter the locomotion of animals (reviewed in). The OFT was performed on day 13 of drug exposure in the sub-chronic study, as described previously. An open field arena (1 m²) was illuminated with dim white light (40 Lux) and monitored with a digital video camera. Locomotor activity of the animals (m) was subsequently blindly scored for 10 min using the EthoVision® 225 XT software (Noldus Information Technology, Wageningen, 226 Netherlands). The arena was cleaned with 10% ethanol solution after each test.

Sucrose preference test (SPT). The SPT may indicate whether certain drugs of abuse interact with reward pathways in the brain to promote hedonic activity, i.e. an indulgence in pleasurable activities. The SPT was performed on days 4 and 14 of drug exposure to assess anhedonic or hedonic manifestations in the sub-chronic study, evident in changes in sucrose consumption as previously described. During this test, rats were presented.
with a free choice between two bottles for 24 h, one containing 0.8% sucrose solution and the other tap water. To eliminate the effects of side preference when drinking, the bottles were changed after 12 hours. Both bottles were weighed to measure the amount of water and sucrose solution consumed after the 24 h period. The preference for sucrose was calculated from the amount of sucrose solution consumed, expressed as a percentage of the total amount of liquid consumed (adapted from31).

**Neurochemical and peripheral analyses.** Blood collection. Trunk blood was collected in pre-chilled heparin tubes, centrifuged at 20 000 x g at 4 °C for 10 min and the plasma stored at −80 °C until the day of analysis32.

Superoxide dismutase (SOD): Analysis of %SOD in plasma was performed using an SOD activity assay kit (BioVision™ Superoxide Dismutase activity assay kit, California, USA, catalogue number: K335-100), utilizing water-soluble tetrazolium (WST)-1 to form a dye following reduction with the superoxide anion. The rate of reduction by sample superoxide is directly related to xanthine oxidase (XO) activity which is inhibited by SOD. The absorbance was read at 450 nm using a Bio-Tek FL600 Microplate Fluorescence Reader (Bio-Tek, Instruments, Inc., 381 Highland Park, Winooski, VT, USA).

Brain dissection. Fresh brain tissue was used for the macro-dissection of the frontal cortex, striatum and hippocampus on an ice-cold slab. These brain regions were first identified according to stereological coordinates and subsequently fixed in relation to anatomical landmarks as previously described33. The frontal cortex, striatum and hippocampus were snap frozen in liquid nitrogen and stored at −80 °C until the day of analysis.

Regional brain lipid peroxidation was assayed using a thiobarbituric acid reactive substances (TBARS) assay kit (Parameter™ thiobarbituric acid reactive substances (TBARS) assay from R&D Systems (Minneapolis, USA; catalogue number KGE013)). Malondialdehyde (MDA) was measured as TBARS, with the total amount of MDA expressed as MDA (µM) and read at 532 nm using a spectrophotometric microplate reader.

Regional brain monoamines: Quantification of frontal cortical, striatal and hippocampal DA, 5-HT and respective metabolites (3,4-dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindolacetic acid (5-HIAA)) as well as NA was performed using a high-performance liquid chromatography (HPLC) system with electrochemical detection (HPLC-EC), previously validated in our laboratory34. The metabolite of NA, 3-methoxy-4-hydroxyphenylglycol (MHPG) was below the limit of detection and therefore not quantified. Sample monoamine concentrations were determined by comparing the area under the peak to that of the internal standard (isoproterenol). All monoamine concentrations were expressed as ng/mg wet weight of brain tissue35. The DA and 5-HT turnover ratios were calculated as DOPAC/DA and 5-HIAA/5-HT, respectively35.

**Statistical analysis.** Graphpad Prism version 7 for windows (Graphpad software, San Diego, USA) and SAS/STAT® Software were used for the statistical analysis and graphical presentations. Histograms, Q-Q plots and the Shapiro Wilk test were used to test for normality of all the data sets. Animal body weight (mean ± SEM) was analysed by two-way analysis of variance (ANOVA) (with drug exposure and days of weight as the two factors) with repeated measures for different days of weight measured followed by Bonferroni post-hoc analyses. To compare three or more exposure groups, one-way ANOVA was used followed by appropriate post-hoc testing using Dunnett’s or Bonferroni multiple comparison. The nonparametric Kruskal-Wallis test was used if the assumptions of ANOVA were violated. Statistical analysis of the sucrose preference test was performed by two-way ANOVA (with drug exposure and days of testing as the two factors) with repeated measures for different sucrose preference days (days 4 and 14) followed by Bonferroni post-hoc analyses. In all cases data are expressed as the mean ± standard error of the mean (SEM), with a p value of <0.05 deemed statistically significant.

**Results**

A comparative analysis done for all the behavioural, neurochemical and peripheral markers on the two vehicle groups returned no significant differences (data not shown), whereupon the saline vehicle and olive oil vehicle groups were pooled and hereafter referred to jointly as the “vehicle” group.

**Body weight.** All the exposure groups indicated significant and equal growth over the sub-acute and sub-chronic study periods with no significant group differences observed with respect to drug (efavirenz, MA, THC and THC + efavirenz) or vehicle (saline and olive oil) exposure (data not shown).

**Behavioural analysis.** Conditioned place preference (CPP). Sub-acute study: One-way ANOVA revealed a significant main effect of drug exposure (F (5, 66) = 1.39, p < 0.0001). Dunnett’s post-hoc multiple comparison revealed that animals exposed to sub-acute MA (1 mg/kg), THC (0.75 mg/kg) and efavirenz at 5 mg/kg presented with a significant increase in the difference in time spent in the drug-paired compartment compared to the vehicle control group (p = 0.0013, 0.0007 and 0.02, respectively) (Fig. 2A). Animals exposed to sub-acute 10 mg/kg efavirenz displayed no place preference compared to the vehicle control group (p = 0.47) whilst animals exposed to sub-acute 20 mg/kg efavirenz showed a significant decrease in place preference compared to the vehicle control group (p = 0.035) (Fig. 2A).

Sub-chronic study: One-way ANOVA revealed a significant main effect of drug exposure (F (3, 36) = 5.52, p = 0.01). Bonferroni post-hoc multiple comparison indicated a significant increase in place preference in animals sub-chronically exposed to 5 mg/kg efavirenz (p = 0.03) and THC + efavirenz (p = 0.005) compared to the vehicle control group (Fig. 2B), while the latter was no different vs. each drug separately. THC alone (0.75 mg/kg) tended to do the same but did not significantly affect place preference in the CPP test (Fig. 2B).
Open field test (OFT) (sub-chronic study). No significant effect of drug exposure between any of the drug exposure groups on locomotor activity were observed (data not shown).

Sucrose preference test (SPT) (sub-chronic study). A two-way ANOVA with repeated measures indicated a significant main effect of drug exposure (F (3, 44) = 8.63, p = 0.0001) but no significant effect of days (day 4 and 14) (F (1, 44) = 0.03, p = 0.86) on sucrose preference. Bonferroni post hoc test indicated a significant increase in the percentage sucrose consumed between the sub-chronic THC + efavirenz exposed group vs. the vehicle control group on day 4 (p = 0.03) and day 14 (p = 0.001) as well as versus the THC group on day 4 (p = 0.02) and day 14 (p = 0.006) (Fig. 3).

Peripheral analysis (sub-chronic study). Percentage plasma superoxide dismutase activity (%SOD). One-way ANOVA revealed a significant main effect of drug exposure on the %SOD (F (3, 44) = 29.21, p < 0.0001). Bonferroni post-hoc analysis indicated a significant increase in %SOD in the sub-chronic THC (p < 0.0001), efavirenz (p = 0.0009) and THC + efavirenz (p < 0.0001) exposed groups compared to the vehicle control group on day 4 (p = 0.03) and day 14 (p = 0.001) as well as versus the THC group on day 4 (p = 0.02) and day 14 (p = 0.006) (Fig. 4), although no difference was noted in combination exposed animals vs. each drug separately.

Neurochemical analysis (sub-chronic study). Regional brain lipid peroxidation. One-way ANOVA revealed that drug exposure had a significant main effect on frontal cortical (F (3, 44) = 5.99, p = 0.001) and striatal (F (3, 44) = 8.19, p = 0.002) but not hippocampal (F (3, 44) = 1.1, p = 0.35) lipid peroxidation (measured as MDA levels). Bonferroni post hoc testing indicated that frontal cortical and striatal lipid peroxidation was significantly elevated in animals exposed to sub-chronic efavirenz compared to the vehicle control group (p = 0.047 and p = 0.041, respectively) (Fig. 5A, B). Bonferroni post-hoc analysis also indicated that animals exposed to sub-chronic THC + efavirenz had a significant elevation in lipid peroxidation in the frontal cortex (p = 0.03) and striatum (p = 0.002) compared to the vehicle control group and the THC group (p = 0.04 and p = 0.03 respectively) (Fig. 5A, B), although no difference were noted in combination exposed animals vs. efavirenz separately. No significant differences were observed between the sub-chronic drug exposed groups with regards to hippocampal lipid peroxidation (Fig. 5C).

**Figure 2.** Conditioned place preference (CPP) test in (A) the sub-acute and (B) the sub-chronic exposure groups. Data presented as difference in time spent in drug-paired compartment: Time spent during the habituation in the drug-paired compartment (s) – time spent during the post-test in the drug-paired compartment (s). Tetrahydrocannabinol (THC), Efavirenz (EFV), Methamphetamine (MA). *p < 0.05, **p < 0.01, vs. Vehicle (One-way ANOVA, Dunnett’s multiple comparison (sub-acute study) and Bonferroni’s post hoc test (sub-chronic study)).
Regional brain monoamines. All regional brain monoamine levels in the different exposure groups are shown in Table 1.

One-way ANOVA revealed a significant main effect of drug exposure on: Frontal cortical DA ($F (3,44) = 4.39, p = 0.008$), DOPAC ($F (3, 44) = 8.03, p = 0.0002$), 5-HT ($F (3, 44) = 12.4, p < 0.0001$), 5-HIAA ($F (3, 44) = 59.18, p < 0.0001$), 5-HIAA/5-HT ($F (3,44) = 3.24, p < 0.0001$) and NA ($F (3, 44) = 13, p < 0.0001$); Striatal DA ($F (3,44) = 7.7, p = 0.0003$), DOPAC ($F (3, 44) = 12.28, p < 0.0001$), DOPAC/DA ($F (3, 44) = 5.66, p = 0.002$), 5-HT ($F (3, 44) = 14.83, p < 0.0001$), 5-HIAA ($F (3, 44) = 22.27, p < 0.0001$), 5-HIAA/5-HT ($F (3, 44) = 4.57, p = 0.007$) and NA ($F (3, 44) = 4.96, p = 0.005$); Hippocampal DA ($F (3,44) = 7.42, p = 0.0004$), DOPAC ($F (3, 44) = 12.24, p < 0.0001$), DOPA/DA ($F (3, 44) = 3.5, p = 0.03$), 5-HT ($F (3, 44) = 12.92, p = 0.0001$), 5-HIAA ($F (3, 44) = 26.63, p < 0.0001$) and NA ($F (3, 44) = 2.56, p = 0.067$).

Frontal cortex (Table 1, top panel): Bonferroni multiple comparisons indicated that: sub-chronic efavirenz significantly increased DA ($p = 0.048$), DOPAC ($p = 0.01$) and 5-HT ($p = 0.049$) and significantly decreased 5-HIAA ($p < 0.0001$) and 5-HIAA/5-HT ($p < 0.0001$). Sub-chronic THC significantly decreased 5-HT ($p = 0.006$), 5-HIAA ($p < 0.0001$), 5-HIAA/5-HT ($p = 0.0005$) and NA ($p = 0.0003$). Sub-chronic THC + efavirenz significantly increased DA ($p = 0.007$) and DOPAC ($p = 0.002$) and significantly decreased 5-HIAA ($p < 0.0001$), 5-HIAA/5-HT ($p < 0.0001$) and NA ($p = 0.0001$), this all in comparison to the vehicle control group. Compared to the sub-chronic THC + efavirenz group, Bonferroni multiple comparison indicated significantly lower frontal cortical DOPAC in the sub-chronic efavirenz group ($p = 0.047$) and significantly lower frontal cortical DA ($p = 0.04$) and DOPAC ($p = 0.005$) in the THC group.

Striatum (Table 1, middle panel): Bonferroni multiple comparisons indicated that: sub-chronic efavirenz significantly increased DA ($p = 0.048$), 5-HT ($p = 0.002$) and NA ($p = 0.03$) and significantly decreased DOPAC ($p = 0.044$) and DOPAC/DA ($p = 0.03$). Sub-chronic THC significantly decreased DOPAC ($p < 0.0001$), DOPAC/DA ($p = 0.01$), and 5-HIAA ($p < 0.0001$). Sub-chronic THC + efavirenz significantly increased DA ($p = 0.006$) and 5-HT ($p = 0.02$) and NA ($p = 0.047$) and significantly decreased DOPAC ($p = 0.0002$), DOPAC/DA ($p = 0.004$) 5-HIAA ($p < 0.0001$) and 5-HIAA/5-HT ($p = 0.004$), this all in comparison to the vehicle control group (Table 1, middle panel). Bonferroni multiple comparison indicated significantly lower striatal DA ($p = 0.001$) and 5-HT ($p < 0.0001$) in the sub-chronic THC group compared to the sub-chronic THC + efavirenz group.

Figure 3. % Sucrose consumption in the sub-chronic drug exposure groups on day 4 and 14 of drug exposure. Tetrahydrocannabinol (THC); Efavirenz (EFV); Methamphetamine (MA). *p < 0.05, **p < 0.01 vs. Vehicle; $p < 0.05, $$$p < 0.01$ vs. THC (Two-way ANOVA with repeated measures, Bonferroni’s post-hoc test).

Figure 4. Peripheral percentage superoxide dismutase (%SOD) activity in the sub-chronic drug exposure groups. Tetrahydrocannabinol (THC); Efavirenz (EFV); Methamphetamine (MA). **p < 0.01, ****p < 0.0001, vs Vehicle (One-way ANOVA, Bonferroni’s post-hoc test).
Hippocampus (Table 1, bottom panel): Bonferroni multiple comparisons indicated that: sub-chronic efavirenz significantly decreased DA ($p = 0.005$) and DOPAC ($p = 0.002$). Sub-chronic THC significantly decreased DA ($p = 0.04$), DOPAC ($p < 0.0001$), 5-HT ($p = 0.002$) and 5-HIAA ($p < 0.0001$). Sub-chronic THC + efavirenz significantly decreased DA ($p = 0.0003$), DOPAC ($p = 0.0002$), 5-HT ($p = 0.002$) and 5-HIAA ($p < 0.0001$) and increased DOPAC/DA ($p = 0.04$), all in comparison to the vehicle control group (Table 1, bottom panel). Compared to the sub-chronic THC + efavirenz group, Bonferroni multiple comparison indicated significantly lower hippocampal DOPAC/DA in the sub-chronic THC group ($p = 0.045$). No significant differences in hippocampal NA levels were observed between the various exposure groups.

Discussion

This study demonstrates that sub-acute efavirenz (5 mg/kg) significantly increases CPP in rats, similar to that induced by sub-acute MA (1 mg/kg) and THC (0.75 mg/kg). Moreover, higher doses of efavirenz either fail to induce place preference or are frankly aversive. Efavirenz (5 mg/kg) also induced place preference after sub-chronic exposure, together with increased cortico-striatal DA and 5-HT, increased striatal NA, and elevated

![Figure 5. Lipid peroxidation as malondialdehyde (MDA) levels in (A) the frontal cortex, (B) the striatum and (C) the hippocampus in the sub-chronic drug exposure groups. Tetrahydrocannabinol (THC); Efavirenz (EFV); Methamphetamine (MA). *$p < 0.05$, ***$p < 0.001$, vs Vehicle, $^*$ $p < 0.05$ vs THC (One-way ANOVA, Bonferroni's post-hoc test).](image-url)
Interestingly, we observed no locomotor changes in efavirenz (5 mg/kg), THC and THC + efavirenz exposed animals in the sub-chronic study. In fact, a recent study also came to the same conclusion concerning acute or sub-chronic efavirenz, despite exploring higher dosages (25 and 50 mg/kg). Moreover, locomotor activity following cannabinoid administration is either unaltered or suppressed at high (20–30 mg/kg) but not low dosages (0.75 mg/kg) of THC, thus emphasizing the variable nature of oxidative stress markers in plasma and brain. THC and efavirenz evoked similar behavioural and redox responses as well as increased cortico-striatal DA, 5-HT and NA levels, and a reduction in the hippocampus. Only combined sub-chronic THC + efavirenz exposure was hedonic in the SPT, while sub-chronic THC + efavirenz also induced greater cortico-striatal lipid peroxidation, sucrose preference and increase fronto cortical DA and striatal DA and 5-HT vs. THC alone. Neither efavirenz, THC nor efavirenz + THC markedly affected locomotor behaviour.

Considering the sub-acute study data, efavirenz produced place preference only at lower doses (5 mg/kg), as did THC. No other acute or sub-acute studies on efavirenz at this dosage are available for comparison. However, THC has been found to produce a place preference at very low dosages (0.075–0.75 mg/kg), while higher dosages of these drugs (36–38,40,41).

Importantly, sub-chronic (14 days exposure) efavirenz (5 mg/kg) not only induced sustained rewarding effects, but concomitant disturbances in cortico-striatal monoamines as well as profound redox disturbances in blood and brain was also evident (see below). This finding signifies long-lasting neuro-adaptive and neurotoxic changes that very likely underlie the aforementioned drug-seeking behaviour. Indeed, long-lasting bio-behavioural changes are typical of prolonged exposure to drugs of abuse (44,45). Interestingly, Gatch et al. did not demonstrate a CPP after sub-acute efavirenz exposure, although differences in dose and duration of exposure may explain such discrepancies, viz. 5 mg/kg or escalating dosages of 10–20 mg/kg for the CPP conditioning sessions. As noted earlier, the rewarding effects of efavirenz at 5 mg/kg may have been rewarding but was lost at higher doses. Previous studies have indicated that the rewarding effects of THC in the CPP test are dose and time (duration of exposure) dependent, possibly explaining the failure of sub-chronic THC to produce a place preference here, although a tendency towards drug-seeking remains evident. Nevertheless, sub-chronic exposure to combined THC and efavirenz induced a significant place preference, although superiority over either drug alone was not observed.

Drug-seeking behaviour, which involves actively seeking the drug, is often observed as a secondary manifestation with drugs of abuse (reviewed in 46). Interestingly, we observed no locomotor changes in efavirenz (5 mg/kg), THC and THC + efavirenz exposed animals in the sub-chronic study. In fact, a recent study also came to the same conclusion concerning acute or sub-chronic efavirenz, despite exploring higher dosages (25 and 50 mg/kg). Moreover, locomotor activity following cannabinoid administration is either unaltered or suppressed at high (20–30 mg/kg) but not low dosages (0.75 mg/kg) of THC, thus emphasizing the variable nature of

| Table 1. Selected monoamine levels (ng/mg tissue) in regional brain tissue of rats exposed to sub-chronic vehicle (n = 24), efavirenz (5 mg/kg) (n = 12), THC (0.75 mg/kg) (n = 12) and THC + efavirenz respectively. Presented as Mean ± standard error of the mean (SEM). DA, Dopamine; DOPAC, 3,4-Dihydroxyphenylethylacetic acid (DOPAC); 5-HT, Serotonin; 5-Hydroxyindoleacetic acid (5-HIAA), NA, Noradrenaline. *p < 0.05, **p < 0.01 vs Vehicle; *p < 0.05, **p < 0.01 vs THC + efavirenz (One-way ANOVA, Bonferroni post-hoc analysis). |  |
|---|---|---|---|---|
| Frontal cortex |  |
| Vehicle | Efavirenz (5 mg/kg) | THC (0.75 mg/kg) | THC + efavirenz |
| DA | 60.7 ± 27.54 | 301.2 ± 72.57** | 202.9 ± 50.47** | 452 ± 131.8** |
| DOPAC | 40.63 ± 8.733 | 149.4 ± 50.51** | 76.19 ± 24.42** | 197.2 ± 35.71**** |
| DOPAC/DA | 1.661 ± 0.3234 | 0.660 ± 0.1998 | 0.5048 ± 0.26 | 5.98 ± 5.44 |
| 5-HT | 191.6 ± 5.873 | 235.8 ± 9.696* | 129.6 ± 9.56** | 197.1 ± 20.07 |
| 5-HIAA | 201.1 ± 11.64 | 121.2 ± 4.637*** | 87.45 ± 4.53*** | 92.35 ± 3.47**** |
| 5-HIAA/5-HT | 1.067 ± 0.080 | 0.607 ± 0.666*** | 0.71 ± 0.06*** | 0.53 ± 0.057*** |
| NA | 227.5 ± 6.304 | 220 ± 14.83 | 148.2 ± 14.19*** | 144.8 ± 12.42*** |
| Striatum |  |
| DA | 2228 ± 238.7 | 3107 ± 158.4* | 2030 ± 249.3* | 3445 ± 306.7** |
| DOPAC | 1109 ± 162.4 | 731 ± 61.48* | 350 ± 37.2*** | 480 ± 69.65*** |
| DOPAC/DA | 0.626 ± 0.174 | 0.249 ± 0.029* | 0.2 ± 0.03* | 0.15 ± 0.023** |
| 5-HT | 256.8 ± 18.7 | 366.8 ± 28.02*** | 162.1 ± 11.39*** | 339.1 ± 33.29** |
| 5-HIAA | 243.5 ± 13.42 | 260 ± 8.978 | 151.9 ± 17.16*** | 144 ± 9.97*** |
| 5-HIAA/5-HT | 1.027 ± 0.131 | 0.7991 ± 0.1325 | 0.97 ± 0.12 | 0.5 ± 0.07** |
| NA | 81.95 ± 6.985 | 137.6 ± 15.99* | 86.88 ± 9.55 | 132.6 ± 17.32* |
| Hippocampus |  |
| DA | 794.8 ± 223.7 | 189.5 ± 63.72** | 309.1 ± 74.08** | 47.24 ± 11.36*** |
| DOPAC | 384.5 ± 69.62 | 152 ± 31.84** | 42.77 ± 18.77**** | 105.3 ± 32.41*** |
| DOPAC/DA | 0.823 ± 0.197 | 1.93 ± 0.490 | 0.18 ± 0.07** | 3.19 ± 1.42** |
| 5-HT | 234.2 ± 30.91 | 264.6 ± 18.71 | 110.6 ± 18.95** | 111.9 ± 18.67** |
| 5-HIAA | 250.2 ± 13.26 | 205.3 ± 7.501 | 154.8 ± 13.38*** | 123.7 ± 7.76*** |
| 5-HIAA/5-HT | 1.323 ± 0.227 | 0.803 ± 0.042 | 2.07 ± 0.48 | 1.7 ± 0.44 |
| NA | 279.9 ± 26.74 | 345.9 ± 55.9 | 173.3 ± 17.78 | 321.6 ± 70.37 |

---

[41x18]www.nature.com/scientificreports/
for a lack of effect on locomotor activity requires further study. Thus, efavirenz at least establishes hedonic behaviour when combined with THC, with DA reward involvement of frontal cortical and striatal regions. Higher aversive doses of efavirenz (e.g. 20 mg/kg), such high doses increase depressive-like behaviour in rats, thus supportive of a dose-dependent balance between its rewarding effects (risk of abuse) vs. neuropsychiatric side-effects such as depression and anhedonia.

Redox dysregulation is well-described in patients treated with efavirenz. Altered redox in turn alters neurotransmitter release and is implicated in mood and psychotic disorders. Efavirenz treatment is also associated with elevated striatal glutamate levels, which may induce oxidative stress. Alternatively, high dosages of efavirenz are associated with elevated plasma levels of 8-hydroxy-efavirenz, a known pro-oxidant thought to underlie the neuropsychiatric effects of efavirenz. Moreover, neurotoxicity underlies some of the neuropsychological effects of drugs of abuse, involving for eg. DA mediated formation of O₂⁻, H₂O₂, OH and quinone adducts. This is especially the case in DA rich regions of the brain, and where SOD is compromised in its ability to scavenge these reactive intermediates. Indeed, we show here that animals exposed to sub-chronic efavirenz, THC and THC + efavirenz all display significantly increased plasma %SOD activity, although no apparent reinforcing effect is evident in combined THC + efavirenz exposed animals. Moreover, significantly elevated lipid peroxidation was evident in the striatum and frontal cortex, but not the hippocampus, of sub-chronic efavirenz and THC + efavirenz exposed animals, while sub-chronic THC + efavirenz was significantly superior to THC alone regarding regional brain lipid peroxidation, possibly due to THC not increasing cortico-striatal lipid peroxidation alone. Thus, efavirenz exposure increased ROS, this in an attempt to detoxify formed reactive intermediates. Supportive of this, similar findings are noted with cocaine, while efavirenz has also been found to increase endoplasmic reticulum stress and autophagy in human endothelial cells. Importantly, the aforementioned increase in lipid peroxidation co-presented with elevated DA levels in the brain reward areas, viz. frontal cortical and striatum, thus supportive of DA-mediated oxidative stress. However, sub-chronic THC neither increased cortico-striatal nor lipid peroxidation levels, observations that correspond with previous preclinical studies, that could explain the lack of augmentation in THC + efavirenz groups vs. efavirenz alone.

DA plays a crucial role in mediating reward and learning. Sub-chronic efavirenz at 5 mg/kg and THC + efavirenz significantly increased DA levels in the frontal cortex, involved in reward and learning, and the striatum involved in decision making and reward learning. Moreover, increased frontal cortical DOPAC levels was evident in the THC + efavirenz group, possibly supporting elevated DA in this region. Cortico-striatal D₁ receptors drives reward effects as well as the reinforcement of drug seeking behaviour, preference for drugs of abuse, and enhancement of palatability of food. Sub-chronic THC, on the other hand, did not affect cortico-striatal DA or place preference. Interestingly, sub-chronic efavirenz, THC and THC + efavirenz significantly decreased hippocampal DA levels (implicated in memory and reward anticipation), a region rich in high affinity D₂ receptors responsible for maintaining drug-seeking motivation. However increased hippocampal DA turnover in sub-chronic THC + efavirenz groups indicates an increase in DA metabolism, possibly explaining lower DA levels in this region and in line with previous efavirenz studies. Moreover, reduced DA turnover in the striatum after sub-chronic efavirenz, THC and THC + efavirenz exposure suggests diminished DA metabolism via monoamine oxidase (MAO) and thus an increase in DA bioavailability, evinced by the higher DA levels in this brain region, although not significantly so in the THC group. Incidentally, Gatch et al. describe interactions between efavirenz and DA transporters, which may also explain the observed dopaminergic effects in efavirenz- and efavirenz + THC exposed animals.

Drugs of abuse such as LSD, cocaine and MA interact with 5HT receptors or 5-HT transporters, respectively, to increase frontal-cortical DA and 5-HT levels. 5-HT is also involved in emotion and memory processes pertaining to drug addiction. Sub-chronic efavirenz increased frontal cortical and striatal 5-HT levels without noticeable effects on hippocampal 5-HT. Paradoxically, sub-chronic THC reduced frontal cortical 5-HT, possibly also contributing towards unaltered frontal cortical 5-HT observed in the sub-chronic THC + efavirenz group, a finding that may explain THC induced cognitive and memory deficits in rodents (reviewed in). Recently, Gatch et al., 2013 described interactions between efavirenz and 5-HT transporters, supportive of how efavirenz may increase 5-HT levels described here. However, sub-chronic THC and THC + efavirenz significantly
reduced hippocampal 5-HT and 5-HIAA, thus countering the bolstering effect of efavirenz. This might be related to a down regulation of CB1 receptors and a resultant up-regulation of 5-HT1A receptors (see review by 18). Decreased frontal cortical 5-HT turnover in sub-chronic efavirenz, THC and THC + efavirenz groups, and in the striatum of THC + efavirenz exposed rats, suggest increased 5-HT levels due to decreased metabolism, in line with previous studies 10,81. However, no augmenting effects on 5-HT were observed in the THC + efavirenz group vs. either drug alone.

No changes in hippocampal NA levels were observed in any of the exposure groups, although sub-chronic THC and THC + efavirenz significantly decreased frontal cortical NA while sub-chronic efavirenz and THC + efavirenz significantly increased striatal NA. These responses are not unlike cortical hypoadrenergia and striatal hyperadrenergia that have been associated with cognitive deficits and psychosis, respectively 59. Regional brain increases in NA might be a unifying etiological factor in drug abuse, viz. suppressing noradrenergic signaling during chronic use but increasing NA levels in reward circuits 82. Furthermore, low and high doses of THC decrease and increase frontal cortical NA levels, respectively (reviewed in 83). However, chronic efavirenz exposure has been noted to reduce striatal DA, 5-HT and NA 10, although other regions were not assessed. That said, the latter findings were observed at much higher dosages, coinciding with the aversive doses described earlier in the CPP test after sub-acute exposure. The reduction in striatal monoamines 10 possibly correlates with depressive and anxiety-like behaviour associated with efavirenz 2. Indeed, the neuropsychiatric side effects of efavirenz are directly related to its plasma concentration 2, with higher dosages more associated with depression 2. THC + efavirenz did not have augmenting effects on regional NA vs. either drug alone.

Conclusion
Sub-acute efavirenz (5 mg/kg) provokes drug-seeking behaviour that closely parallels that of MA and THC, with higher doses ineffective or aversive. Sub-chronic efavirenz (5 mg/kg) alone or in combination with THC is similarly addictive and hedonic, as well as increases cortico-striatal DA, 5-HT, lipid peroxidation and peripheral oxidative stress. Sub-chronic THC + efavirenz was significantly superior to THC alone regarding regional brain lipid peroxidation, frontal cortical DA, DOPAC, striatal DA, 5-HT and hippocampal DOPAC/DA alterations, and hedonic behaviour, but superior to efavirenz regarding increased frontal cortical DOPAC, suggesting synergistic effects.

The neuropsychiatric effects of efavirenz are widely evident in the literature, as is the problem of HIV-associated neuropsychiatric disorder (HAND) 52. Inflammation and altered redox status modifies monoaminergic transmission to contribute to the manifestation of depression, psychosis and addictive behavior 58,59,83. With efavirenz known to be brain penetrant and to promote the formation of a pro-oxidant metabolite, 8-OH efavirenz, this paper brings together startling evidence that efavirenz-associated redox disturbances and altered limbic brain monoamines lay the foundation for addictive-like behavior. Although measuring redox parameters may represent a simple biomarker to confirm efavirenz-associated neuropsychiatric effects, redox dysfunction characterizes many neuropsychiatric disorders thus complicating any such interpretation 59. Nevertheless, our data suggests that targeting cellular redox biology pharmacologically may reduce or prevent these adverse effects. While it may not always be possible to restrict the use of efavirenz due to its superior efficacy vs. other anti-HIV drugs 1, adjunctive treatment with a brain and peripherally active antioxidant, such as N-acetyl cysteine (NAC), may offer prophylactic and therapeutic benefits for efavirenz-associated drug seeking behavior.

This work therefore proposes possible mechanisms for efavirenz associated drug-seeking behaviour while also reiterating the abuse potential of efavirenz-cannabis combinations. The findings hint towards the possible treatment of Nyope addiction with antioxidants, which may aid in the development of new strategies to diminish these effects and to improve ART.

References
1. Staszewski, S. et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N. Engl. J. Med. 341, 1865–1873 (1999).
2. Dalwadi, D., Ozuna, L., Harvey, B., Viljoen, M. & Schetz, J. Adverse neuropsychiatric events and recreational use of efavirenz and other HIV-1 antiretroviral drugs. Pharmacol Rev. in press (2018).
3. Marzolini, C. et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15, 71–75 (2001).
4. Kryst, J., Kawalect, P. & Pilc, A. Efavirenz-based regimens in antiretroviral-naive HIV-infected patients: a systematic review and meta-analysis of randomized controlled trials. PLoS one 10, e0124279 (2015).
5. Almond, L. M., Hoggard, P. G., Edirisinghe, D., Khoo, S. H. & Back, D. J. Intracellular and plasma pharmacokinetics of efavirenz in patients. Ann. N. Y. Acad. Sci. 1213, 70–80 (2010).
6. Gatch, M. B. et al. The HIV antiretroviral drug efavirenz has LSD-like properties. Neuropsychopharmacol 38, 2373 (2013).
7. Schmitt, K. C. & Reith, M. E. Regulation of the dopamine transporter. Prog. Neurobiol. 81, 133–178 (2007).
8. Sora, I. et al. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc. Natl. Acad. Sci. USA 98, 5300–5305 (2001).
9. Mokwena, K. E. The Novel Psychoactive Substance ‘Nyope’Brings Unique Challenges to Mental Health Services in South Africa. Int J Emer Mental Health Human Resilience 17, 251–252 (2015).
10. Yamura, H. et al. Effect of dupilutegravir plasma concentration on central nervous system side effects. Anxity 3, 7 (2017).
11. Goldstein, R. Z. & Volkow, N. D. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am. J. Psychiatry 159, 1642–1650 (2002).
12. Patkar, O. L., Belmer, A. & Bartlett, S. E. Recent Advances in Drug Addiction Research and Clinical Applications. Chapter 5: Contribution of Noradrenaline, Serotonin, and the Basal Ganglia to Addiction. Implications for Novel Pharmacotherapies for AUDs (2016).
13. Gibbs, M. E. & Summers, R. J. Role of adrenergic subtypes in memory consolidation. Prog. Neurobiol. 67, 345–391 (2002).
14. Müller, C. P., Carey, R. J., Huston, J. P. & Silva, M. A. D. S. Serotonin and psychostimulant addiction: focus on 5-HT1A receptors. Prog. Neurobiol. 81, 133–178 (2007).
15. Cunha-Oliveira, T., Rego, A. C. & Oliveira, C. R. Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs. Brain Res. Rev. 58, 192–208 (2008).
16. Cavalcante, G. I. T. et al. HIV antiretroviral drug Efavirenz induces anxiety-like and depression-like behavior in rats: evaluation of neurotransmitter alterations in the striatum. *Eur. J. Pharmacol.* **799**, 7–15 (2017).

17. Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M. & Altman, D. G. Animal research: reporting in vivo experiments: the ARRIVE guidelines. *Br. J. Pharmacol.* **160**, 1577–1579 (2010).

18. Möller, M. et al. Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine. *Brain Behav. Immun.* **30**, 156–167 (2013).

19. Zakharova, E., Leoni, G., Kichko, I. & Izenwasser, S. Differential effects of methamphetamine and cocaine on conditioned place preference and locomotor activity in adult and adolescent male rats. *Behav. Brain Res.* **198**, 45–50 (2009).

20. Braida, D.,Issue, S., Pegorini, S. & Sala, M. Δ9-Tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. *Eur. J. Pharmacol.* **506**, 63–69 (2004).

21. Iurria, S. J. A method for obtaining randomized block designs in preclinical studies with multiple quantitative blocking variables. *Pharmacol. Ther.* **10**, 169–174 (2011).

22. Sharma, P., Murthy, P. & Bharath, M. M. Chemistry, metabolism, and toxicology of cannabinoid clinical implications. *Iran. J. Psychiatry* **7**, 149–156 (2012).

23. Gaur, P. K., Mishra, S., Bajpai, M. & Mishra, A. Enhanced oral bioavailability of efavirenz by solid lipid nanoparticles: in vitro drug release and pharmacokinetics studies. *Biomed. Res. Int.* **2014**, 636404 (2014).

24. da Silveira, N. S., de Oliveira-Silva, G. L. & de Freitas Lamanes, B. da Silva Prado, Ligia Carolina & Bispo-da-Silva, L. B. The aversive, anxiety-like, and verapamil-sensitive psychostimulant effects of pulegone. *Biocl. Infect Drug Bull.* **37**, 771–778 (2014).

25. Bardo, M. & Bevins, R. A. Conditioned place preference: what does it add to our preclinical understanding of drug reward? *Psychopharmacology (Berl.)* **153**, 31–43 (2000).

26. Tischchenke, T. M. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. *Prog. Neurobiol.* **63**, 241–320 (2001).

27. Malanga, C., Pejchal, M. & Kosofsky, B. E. Prenatal exposure to cocaine alters the development of conditioned place-preference to cocaine in adult mice. *Pharmacol Biochem Behav* **87**, 462–471 (2007).

28. Weinshenker, D. & Schroeder, J. P. There and back again: a tale of norepinephrine and drug addiction. *Neuropsychopharmacology* **32**, 1433 (2007).

29. Gould, T. D., Dao, D. T. & Kovacsics, C. E. The open field test. *Mood and anxiety related phenotypes in mice: Characterization using behavioral tests*, 1–20 (2009).

30. Rygula, R. et al. Anhedonia and motivational deficits in rats: impact of chronic social stress. *Behav. Brain Res.* **162**, 127–134 (2005).

31. Taffe, M. A., Creehan, K. M. & Vandewater, S. A. Cannabidiol fails to reverse hypothermia or locomotor suppression induced by drug primings. *Brain Res.* **1050**, 53–65 (2005).

32. Der-Avakian, A. & Markou, A. The neurobiology of anhedonia and other reward-related deficits. *CNS Neurosci Therap* **14**, 295–314 (2008).

33. Spijker, S. In *Drug safety* (ed. Li, K. W.) 13–26 (Springer, 2011).

34. Harvey, B. H., Brand, L., Jeeva, Z. & Stein, D. J. Cortical/hippocampal monoamines, HPA-axis changes and aversive behavior following stress and restress in an animal model of post-traumatic stress disorder. *Physiol. Behav.* **87**, 881–890 (2006).

35. Gemmel, M. et al. Developmental fluoxetine and prenatal stress effects on serotonin, dopamine, and synaptophysin density in the PFC and hippocampus of offspring at weaning. *Dev. Psychobiol.* **58**, 315–327 (2016).

36. Berridge, K. C. & Kringelbach, M. L. Pleasure systems in the brain. *Neuron* **948**, 155–158 (2002).

37. Cheer, J., Kendall, D. & Marsden, C. Cannabinoid receptors and reward in the rat: a conditioned place preference study. *Psychopharmacology (Berl.)* **151**, 25–30 (2000).

38. Tzschentke, T. M. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. *Prog. Neurobiol.* **63**, 241–320 (2001).

39. Do Couto, B. R., Aguilar, M., Rodriguez-Arias, M. & Minarro, J. Long-lasting rewarding effects of morphine induced by drug primings. *Neuropharmacology* **57**, 169–174 (2011).

40. Fumaz, C. R. *Δ9-Tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. Eur. J. Pharmacol.* **506**, 63–69 (2004).

41. Bardo, M. & Bevins, R. A. Conditioned place preference: what does it add to our preclinical understanding of drug reward? *Psychopharmacology (Berl.)* **153**, 31–43 (2000).

42. Gaur, P. K., Mishra, S., Bajpai, M. & Mishra, A. Enhanced oral bioavailability of efavirenz by solid lipid nanoparticles: in vitro drug release and pharmacokinetics studies. *Biomed. Res. Int.* **2014**, 636404 (2014).

43. Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M. & Hintzen, A. The pharmacology of lysergic acid diethylamide: a review. *CNS Neurosci Therap* **14**, 295–314 (2008).

44. Goodwin, A. K. An intravenous self-administration procedure for assessing the reinforcing effects of hallucinogens in nonhuman primates. *J. Pharmacol. Toxicol. Methods* **82**, 31–36 (2016).

45. Crespes, M. S. & Aberj, J. A. Neuropsychiatric complications of antiretroviral therapy. *Drug safety* **29**, 865–874 (2006).

46. Brown, J. E., Kassouny, M. & Cross, J. K. Kinetic studies of food intake and sucrose solution preference by rats treated with low doses of Δ9-tetrahydrocannabinol in rats. *Neuropsychopharmacology* **32**, 2036 (2007).

47. Taffe, M. A., Creehan, K. M. & Vandewater, S. A. Cannabidiol fails to reverse hypothermia or locomotor suppression induced by Δ9-tetrahydrocannabinol in Sprague-Dawley rats. *Br. J. Pharmacol.* **172**, 1783–1791 (2015).

48. 9-Tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. *Brain Res. 948*, 155–158 (2002).

49. Brown, J. E., Kassouny, M. & Cross, J. K. Kinetic studies of food intake and sucrose solution preference by rats treated with low doses of Δ9-tetrahydrocannabinol. *Behav. Biol.* **20**, 104–110 (1977).

50. Graham, D. L., Hoppenot, R., Hendryx, A. & Self, D. W. Differential ability of D1 and D2 dopamine receptor agonists to induce and modulate expression and reinstatement of cocaine place preference in rats. *Psychopharmacology (Berl.)* **191**, 719–730 (2007).

51. Thomas, K. C. & Kringlebak, M. L. Pleasure systems in the brain. *Neuron* **948**, 155–158 (2002).

52. Gaur, P. K., Mishra, S., Bajpai, M. & Mishra, A. Enhanced oral bioavailability of efavirenz by solid lipid nanoparticles: in vitro drug release and pharmacokinetics studies. *Biomed. Res. Int.* **2014**, 636404 (2014).

53. Gosnell, B. A. Sucrose intake enhances behavioral sensitization produced by cocaine. *Brain Res. 1031*, 194–201 (2005).

54. Berridge, K. C. & Kringelbach, M. L. Pleasure systems in the brain. *Neuron* **948**, 155–158 (2002).

55. Avena, N. M. & Hoebel, B. G. Amphetamine-sensitized rats show sugar-induced hyperactivity (cross-sensitization) and sugar hyperphagia. *Pharmacol Biochem Behav* **74**, 635–639 (2003).

56. Tzschentke, T. M. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. *Prog. Neurobiol.* **63**, 241–320 (2001).

57. Lertpayakul, W. et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. *Behav. Biol.* **20**, 104–110 (1977).

58. Tzschentke, T. M. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. *Prog. Neurobiol.* **63**, 241–320 (2001).
58. Möller, M., Swanepoel, T. & Harvey, B. H. Neurodevelopmental Animal Models Reveal the Convergent Role of Neurotransmitter Systems, Inflammation, and Oxidative Stress as Biomarkers of Schizophrenia: Implications for Novel Drug Development. *ACS Chem Neurosci* 6, 987–1016 (2015).

59. Brand, J., Möller, M. & Harvey, B. A review of biomarkers in mood and psychotic disorders: a dissection of clinical vs. preclinical correlates. *Curr Neuropharmacoal* 13, 324–368 (2015).

60. Barron, H., Hafizi, S., Andreazza, A. C. & Mizrahi, R. Neuroinflammation and oxidative stress in psychosis and psychosis risk. *Int J Mol Sci* 18, 651 (2017).

61. Decloedt, E. H. & Maartens, G. Neuronal toxicity of efavirenz: a systematic review. *Expert opinion on drug safety* 12, 841–846 (2013).

62. Leshner, A. I. Addiction is a brain disease, and it matters. *Sci* 278, 45–47 (1997).

63. O’Dell, S. J., Weihmuller, F. B. & Marshall, J. F. Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity. *Brain Res* 564, 256–260 (1991).

64. Dietrich, J. *et al.* Acute or repeated cocaine administration generates reactive oxygen species and induces antioxidant enzyme activity in dopaminergic rat brain structures. *Neuropharmacology* 48, 965–974 (2005).

65. Weiß, M. *et al.* Efavirenz causes oxidative stress, endoplasmic reticulum stress, and autophagy in endothelial cells. *Cardiovas Toxicol* 16, 90–99 (2016).

66. Calderón, G., Esquivel, G., García, E., Osnaya, N. & Juárez Olguín, H. Effects of marijuana and diazepam on lipid peroxidation, Na, K-ATPase, and levels of glutathione and 5-HTP in rat brain. *Acta. Biol. Hung.* 61, 135–144 (2010).

67. Coskun, Z. M. & Bolkent, S. Evaluation of Delta(9)-tetrahydrocannabinol metabolites and oxidative stress in type 2 diabetic rats. *Iran. J. Basic Med. Sci.* 19, 154–158 (2016).

68. Goodman, A. Neurobiology of addiction: An integrative review. *Biochem. Pharmacol.* 75, 266–322 (2008).

69. Koob, G. F. Neurobiology of addiction: toward the development of new therapies. *Ann. N. Y. Acad. Sci.* 909, 170–185 (2000).

70. Kalivas, P. W. & McFarland, K. Brain circuitry and the reinstatement of cocaine-seeking behavior. *Psychopharmacology (Berl.)* 168, 44–56 (2003).

71. Balleine, B. W., Delgado, M. R. & Hikosaka, O. The role of the dorsal striatum in reward and decision-making. *J. Neurosci.* 27, 8161–8165 (2007).

72. Beaulieu, J.-M. & Gainetdinov, R. R. The physiology, signaling, and pharmacology of dopamine receptors. *Pharmacol. Rev.* 63, 182–217 (2011).

73. Karasinska, J. M., George, S. R., Cheng, R. & O’Dowd, B. F. Deletion of dopamine D1 and D3 receptors differentially affects spontaneous behaviour and cocaine-induced locomotor activity, reward and CREB phosphorylation. *Eur. J. Neurosci.* 22, 1741–1750 (2005).

74. Cooper, S. & Al-Naser, H. Dopaminergic control of food choice: contrasting effects of SKF 38393 and quinpirole on high-palatability food preference in the rat. *Neuropharmacology* 50, 953–963 (2006).

75. Seeman, P. Targeting the dopamine D2 receptor in schizophrenia. *Expert opinion on therapeutic targets* 10, 515–531 (2006).

76. Kirby, L., Zeeb, F. & Winstanley, C. Contributions of serotonin in addiction vulnerability. *Neuropharmacology* 61, 421–432 (2011).

77. Müller, N. & Schwarz, M. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. *Mol. Psychiatry* 12, 988–1000 (2007).

78. Halberstadt, A. L. & Geyer, M. A. Characterization of the head-twitch response induced by hallucinogens in mice. *Psychopharmacology (Berl.)* 227, 727–739 (2013).

79. Egerton, A., Allison, C., Brett, R. R. & Pratt, J. A. Cannabinoids and prefrontal cortical function: insights from preclinical studies. *Neurosci Biobehav Rev* 30, 680–695 (2006).

80. Vitals, X. *et al.* Cognitive impairment induced by delta9-tetrahydrocannabinol occurs through heteromers between cannabinoid CB1 and serotonin 5-HT2A receptors. *PLoS biology* 13, e1002194 (2015).

81. Molina-Holgado, F., Molina-Holgado, E., Leret, M. L., González, M. I. & Reader, T. A. Distribution of indoleamines and [3 H] dopamine in rat brain. *J Neurosci Biobehav Rev* 30, 680–695 (2006).

82. Fitzgerald, P. J. Elevated norepinephrine may be a unifying etiological factor in the abuse of a broad range of substances: alcohol, nicotine, marijuana, heroin, cocaine, and caffeine. *Substance abuse: research and treatment* 7, SART S13019 (2013).

83. Beardsley, P. M. & Hauser, K. F. Glial modulators as potential treatments of psychostimulant abuse. *Adv Pharmacol.* 69, 1–69 (2014).

Acknowledgements

The authors would like to thank Antoinette Fick and Kobus Venter (Good laboratory practice manager and assistant at the Vivarium of the North-West University), the North-West University Statistical Consultation Services, as well as Walter Dreyer and Francois Viljoen, for their assistance with ELISA and HPLC analyses, respectively. This study was supported by the South African Medical Research Council (MRC) (M. Möller) and the National Research Foundation (NRF; M. Möller; Grant UID99276). The opinions, findings and conclusions or recommendations expressed in any publication generated by NRF supported research are those of the authors, and that the NRF accepts no liability whatsoever in this regard.

Author Contributions

J. Fourie assisted in the design of the study and along with M. Möller conducted the behavioural experiments, undertook the statistical analyses and prepared the first draft of the manuscript. B.H. Harvey also advised on the study design and statistical analysis. M. Möller and B.H. Harvey supervised the study, assisted in the interpretation of the study data, and finalized the manuscript for publication.

Additional Information

Competing Interests: The authors declare that there is no competing interest regarding the publication of this article. Efavirenz was a kind sponsor from Aspen, South Africa.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
